Tag: Outlook Therapeutics

Outlook Therapeutics shares have more than doubled – and then some – over the past month, but the price action ...

July is shaping up as a binary-riddled month for the small-cap biopharma. Two weeks after shareholders cast decisive ballots on ...

Shares of Outlook Therapeutics have exploded higher since late March, surging roughly 950% after the FDA accepted the company’s regulatory ...

Outlook Therapeutics has escaped the threat of expulsion from the Nasdaq Capital Market, but the relief is tempered by a ...

The stock has more than doubled since late May, but the coming weeks will determine whether that momentum is sustainable ...

Outlook Therapeutics enters a high-stakes July with two pivotal events that will shape its future. On the 16th, shareholders must ...

The countdown has begun for Outlook Therapeutics, with the U.S. Food and Drug Administration setting a binding decision date of ...

A director at Outlook Therapeutics has put more than $5 million of his own money on the line, scooping up ...

Investor attention within the biotechnology space is increasingly focused on Outlook Therapeutics. The company is approaching several pivotal operational milestones ...

The biopharmaceutical company Outlook Therapeutics is approaching a pivotal transition, moving from clinical development into the commercial phase. This shift ...